Stock 575 REGENT PACIFIC GROUP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Regent Pacific Group Limited Hong Kong S.E.

Equities

575

KYG3042R1231

Pharmaceuticals

End-of-day quote Hong Kong S.E.
Other stock markets
 06:00:00 2024-02-04 pm EST 		5-day change 1st Jan Change
0.47 HKD -.--% Intraday chart for Regent Pacific Group Limited -17.54% -24.19%
Mar. 27 Regent Pacific Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 25 Qujing Black Gold Energy Co., Ltd. entered into a sale and purchase agreement to acquire 25% stake in West China Coking & Gas Company Limited from Regent Pacific Group Limited for CNY 8 million. CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 87.02 75.09 28.3 57.57 47.4 24.28
Enterprise Value (EV) 1 76 68.71 33.91 66.37 49.08 36.57
P/E ratio -3.14 x -2.42 x -0.43 x -1.83 x -3.73 x -0.67 x
Yield - - - - - -
Capitalization / Revenue 16.5 x 12 x 173 x 47.5 x 2.81 x 694 x
EV / Revenue 14.4 x 11 x 207 x 54.8 x 2.91 x 1,045 x
EV / EBITDA -21.5 x -27.9 x -3.55 x -10.9 x 5.7 x -6.3 x
EV / FCF 12.5 x 7.15 x 4.12 x 20.8 x 4.32 x 5.47 x
FCF Yield 8.03% 14% 24.3% 4.82% 23.1% 18.3%
Price to Book 0.55 x 0.59 x 0.45 x 1.14 x 1.22 x 9.35 x
Nbr of stocks (in thousands) 91,863 91,863 91,863 119,971 119,971 120,017
Reference price 2 0.9473 0.8174 0.3081 0.4798 0.3951 0.2023
Announcement Date 4/27/18 4/18/19 4/29/20 4/26/21 4/26/22 4/26/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 5.277 6.254 0.164 1.212 16.84 0.035
EBITDA 1 -3.536 -2.461 -9.543 -6.097 8.607 -5.806
EBIT 1 -31.62 -30.56 -37.64 -25.53 -15.17 -30.77
Operating Margin -599.19% -488.65% -22,949.39% -2,106.6% -90.08% -87,925.71%
Earnings before Tax (EBT) 1 -30.34 -33.76 -64.73 -26.16 -15.09 -36.01
Net income 1 -27.36 -31.09 -66.05 -24.4 -12.6 -36.43
Net margin -518.46% -497.07% -40,273.17% -2,012.79% -74.79% -104,077.14%
EPS 2 -0.3022 -0.3384 -0.7190 -0.2624 -0.1060 -0.3040
Free Cash Flow 1 6.1 9.611 8.225 3.198 11.35 6.684
FCF margin 115.6% 153.68% 5,015.47% 263.88% 67.38% 19,097.5%
FCF Conversion (EBITDA) - - - - 131.87% -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/27/18 4/18/19 4/29/20 4/26/21 4/26/22 4/26/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - 5.61 8.8 1.68 12.3
Net Cash position 1 11 6.37 - - - -
Leverage (Debt/EBITDA) - - -0.5877 x -1.443 x 0.1953 x -2.117 x
Free Cash Flow 1 6.1 9.61 8.23 3.2 11.4 6.68
ROE (net income / shareholders' equity) -16.1% -21.8% -69.8% -43.3% -28.3% -176%
ROA (Net income/ Total Assets) -10.3% -11.8% -20.4% -19.2% -13.3% -43.4%
Assets 1 266.7 263.3 324.4 127.3 94.67 83.85
Book Value Per Share 2 1.730 1.380 0.6800 0.4200 0.3200 0.0200
Cash Flow per Share 2 0.0200 0.0100 0 0.0200 0.0100 0
Capex 1 0.01 0.07 0.01 0.01 0.04 0.01
Capex / Sales 0.17% 1.09% 4.88% 0.58% 0.26% 34.29%
Announcement Date 4/27/18 4/18/19 4/29/20 4/26/21 4/26/22 4/26/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.99% 704B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+28.25% 577B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.36% 348B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.51% 327B
ABBVIE INC. Stock AbbVie Inc.
+4.88% 288B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.65% 234B
NOVARTIS AG Stock Novartis AG
+4.93% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 194B
AMGEN INC. Stock Amgen Inc.
-4.50% 147B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 575 Stock
  4. 575 Stock
  5. Financials Regent Pacific Group Limited